Last Updated on October 5, 2024 by The Health Master
USFDA
Zydus Lifesciences has found itself in hot water after the US Food and Drug Administration inspection (USFDA inspection) followed by issuing a stern warning letter to the company.
The regulator cited multiple manufacturing lapses at the drugmaker’s plant in Gujarat.
Key Violations and Consequences:
- Inadequate Contamination Investigations: The USFDA criticized Zydus for failing to thoroughly investigate contamination incidents at its Jarod-based plant. This included neglecting to examine all impacted batches, manufacturing equipment, and testing methods.
- Cross-Contamination Events: The regulator found that the facility had experienced multiple cross-contamination events over a three-month period.
- Glass Particulate Contamination: Zydus was also flagged for failing to adequately investigate and address glass particulate contamination in batches of Cyanocobalamin Injection.
- Substandard Aseptic Practices: The USFDA noted that the company’s procedures for preventing microbiological contamination were inadequate, including the validation of aseptic and sterilization processes.
USFDA Demands Corrective Action:
In response to these violations, the USFDA has demanded a detailed remediation plan from Zydus.
The plan must outline specific timelines for addressing the identified contamination hazards.
Additionally, the regulator has advised the company to seek external consulting expertise to ensure compliance with good manufacturing practices (GMP).
Potential Consequences of Non-Compliance:
If Zydus fails to address these issues promptly and effectively, the USFDA could take significant action.
This could include withholding approval for new applications, suspending existing approvals, or even imposing import restrictions.
The Importance of GMP Compliance:
The USFDA’s warning letter underscores the critical importance of adhering to GMP standards in the pharmaceutical industry.
These standards are designed to ensure the safety, quality, and efficacy of drug products.
Failure to comply with GMP can have serious consequences for both patients and manufacturers.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA inspection with positive VAI to Dr. Reddy’s Lab for its API facility
Over 340 Pharma Companies overdue for USFDA inspection in India and China
USFDA issues EIR for Marksans Pharma Goa facility
USFDA inspection with positive VAI to Strides Pharma at Chennai
USFDA grants VAI classification to Dr Reddy’s at Visakhapatnam
Joint raid exposes illegal sale of Tramadol
DCA Telangana seizes huge quantity of Cough Syrup
Key components of Uniform Code for Marketing Practices in Medical Devices (UCMPMD) 2024
NPPA fixed retail price of 62 formulations: September 2024
First USFDA approval granted for Lidocaine Hydrochloride Injection: Aurobindo
USFDA issues warning letters to two Chinese firms over data integrity concerns
China’s drug regulator approves MPOX vaccine for Clinical Trial
USFDA approval granted for Albendazole Tablets USP, 200 mg: Alembic
Pharma Industry seeks relief: Decriminalization of DPCO provisions
QR Code Mandate: Pharma Industry calls for Financial Support
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
